Charlotte Poile

Leicester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma.

Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 27, 2025

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

Journal: Nature communications
Published: June 01, 2025

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.

Journal: Nature communications
Published: October 11, 2024

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres.

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres.

Journal: BMJ open
Published: November 22, 2023

A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.

A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.

Journal: Nature communications
Published: October 04, 2023

Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways.

Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways.

Journal: Genes, chromosomes & cancer
Published: May 03, 2023

BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms.

BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms.

Journal: Oncogene
Published: July 15, 2022

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial.

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial.

Journal: EClinicalMedicine
Published: January 07, 2022

Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.

Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.

Journal: The Lancet. Oncology
Published: November 05, 2021

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.

Journal: The Lancet. Oncology
Published: June 12, 2021

Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.

Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.

Journal: Nature communications
Published: June 08, 2021

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.

Journal: Nature communications
Published: September 18, 2020
Showing 1-12 of 12

Last Updated: 09/26/2026